ANDA 91050, held by Chartwell Rx. Abacavir Sulfate.
As of Nov 16, 2026, ANDA 91050 (Abacavir Sulfate), held by Chartwell Rx, was first approved by FDA on Oct 28, 2016, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 28, 2016 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Abacavir SulfateEQ 300MG BASE · tablet;oral | Abacavir Sulfate | Rx |
| Apr 28, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Apr 28, 2023 | Supplement 11Labeling · Standard review | Approved | None posted |
| Apr 28, 2023 | Supplement 10Labeling · Standard review | Approved | None posted |
| Oct 28, 2016 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters